SI2944306T1 - Formulacije antagonista VEGF, primerne za intravitrealno dajanje - Google Patents
Formulacije antagonista VEGF, primerne za intravitrealno dajanjeInfo
- Publication number
- SI2944306T1 SI2944306T1 SI200732171T SI200732171T SI2944306T1 SI 2944306 T1 SI2944306 T1 SI 2944306T1 SI 200732171 T SI200732171 T SI 200732171T SI 200732171 T SI200732171 T SI 200732171T SI 2944306 T1 SI2944306 T1 SI 2944306T1
- Authority
- SI
- Slovenia
- Prior art keywords
- formulations suitable
- vegf antagonist
- intravitreal administration
- antagonist formulations
- intravitreal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81448406P | 2006-06-16 | 2006-06-16 | |
EP15169936.0A EP2944306B1 (en) | 2006-06-16 | 2007-06-14 | Vegf antagonist formulations suitable for intravitreal administration |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2944306T1 true SI2944306T1 (sl) | 2021-04-30 |
Family
ID=38834013
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200732171T SI2944306T1 (sl) | 2006-06-16 | 2007-06-14 | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
SI200731264T SI2364691T1 (sl) | 2006-06-16 | 2007-06-14 | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200731264T SI2364691T1 (sl) | 2006-06-16 | 2007-06-14 | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
Country Status (22)
Country | Link |
---|---|
US (14) | US7608261B2 (sl) |
EP (4) | EP2944306B1 (sl) |
JP (2) | JP5216002B2 (sl) |
KR (1) | KR101406811B1 (sl) |
CN (2) | CN104434770A (sl) |
AU (1) | AU2007261536B2 (sl) |
BR (1) | BRPI0713749B8 (sl) |
CA (1) | CA2654510C (sl) |
CY (2) | CY1114244T1 (sl) |
DK (2) | DK2944306T3 (sl) |
ES (2) | ES2406764T3 (sl) |
HK (1) | HK1204580A1 (sl) |
HU (1) | HUE053612T2 (sl) |
IL (1) | IL195788A (sl) |
LT (1) | LT2944306T (sl) |
MX (1) | MX2008016124A (sl) |
PL (2) | PL2364691T3 (sl) |
PT (2) | PT2364691E (sl) |
RU (1) | RU2432155C3 (sl) |
SI (2) | SI2944306T1 (sl) |
WO (1) | WO2007149334A2 (sl) |
ZA (1) | ZA200809827B (sl) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1934255B (zh) * | 2003-08-27 | 2012-07-11 | 奥普索特克公司 | 用于治疗眼新血管疾病的组合治疗 |
ES2548238T3 (es) | 2005-03-25 | 2015-10-15 | Regeneron Pharmaceuticals, Inc. | Formulaciones antagonistas de VEGF |
EP2004697A2 (en) | 2006-04-07 | 2008-12-24 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
DK2944306T3 (da) | 2006-06-16 | 2021-03-08 | Regeneron Pharma | Egnede VEGF-antagonistformuleringer til intravitreal administration |
US7752757B2 (en) | 2007-01-18 | 2010-07-13 | Eveready Battery Company, Inc. | Shaving system with gas-generating cell |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
CA2813587C (en) | 2010-10-06 | 2019-01-15 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
KR20220097542A (ko) | 2011-01-13 | 2022-07-07 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
RS57339B1 (sr) | 2011-01-28 | 2018-08-31 | Sanofi Biotechnology | Ljudska antitela za pcsk9 za primenu u postupcima tretiranja posebnih grupa pacijenata |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
CA2848201C (en) | 2011-09-16 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
PT3384903T (pt) | 2011-11-18 | 2020-06-25 | Regeneron Pharma | Micropartícula contendo proteína terapêutica revestida com polímero biodegradável para uso médico |
CN107115294B (zh) * | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
NZ627859A (en) | 2012-01-23 | 2015-09-25 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
TW201400122A (zh) * | 2012-06-01 | 2014-01-01 | Ophthotech Corp | 包含抗-pdgf適體及vegf拮抗劑之組合物 |
AR091817A1 (es) | 2012-06-01 | 2015-03-04 | Novartis Ag | Jeringa |
AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
AU2013100360B4 (en) * | 2012-07-03 | 2013-05-16 | Novartis Ag | Device |
DE202012011016U1 (de) * | 2012-07-03 | 2012-11-28 | Novartis Ag | Aflibercept-Spritze |
JOP20200175A1 (ar) * | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
JP6408492B2 (ja) | 2013-02-18 | 2018-10-17 | ヴェジェニクス プロプライエタリー リミテッドVegenics Pty Limited | リガンド結合分子およびその使用 |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
MX2015016887A (es) | 2013-06-07 | 2016-07-26 | Regeneron Pharma | Metodos para inhibir la aterosclerosis mediante la administracion de un inhibidor de pcsk9. |
MX2016000364A (es) | 2013-07-12 | 2016-05-09 | Ophthotech Corp | Metodos para tratar o prevenir afecciones oftalmologicas. |
WO2015011199A1 (en) | 2013-07-23 | 2015-01-29 | Novaliq Gmbh | Stabilized antibody compositions |
WO2015023596A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
CN103622961B (zh) * | 2013-09-06 | 2016-03-02 | 武汉光谷百桥国际生物科技有限公司 | 一种非肽类缓激肽b2受体激动剂在促进毛发生长方面的应用 |
US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
EP3071181B1 (en) | 2013-11-18 | 2021-03-24 | Formycon AG | Pharmaceutical composition of an anti-vegf antibody |
CN106536561A (zh) | 2014-05-01 | 2017-03-22 | 豪夫迈·罗氏有限公司 | 抗‑因子d抗体变体及其用途 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US10544232B2 (en) | 2014-07-16 | 2020-01-28 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody |
CN107076750B (zh) | 2014-07-18 | 2020-06-23 | 赛诺菲 | 用于预测疑似患有癌症的患者使用阿柏西普的治疗结果的方法 |
CN104940926B (zh) * | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
TWI761959B (zh) * | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
BR112017014376A2 (pt) | 2015-01-28 | 2018-05-02 | Pfizer | formulação aquosa estável de anticorpos antifator de crescimento endotelial vascular (vegf) e uso |
KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
CN107922507B (zh) | 2015-08-18 | 2022-04-05 | 瑞泽恩制药公司 | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 |
CN108348462B (zh) * | 2015-10-16 | 2021-10-15 | 瑞泽恩制药公司 | 稳定蛋白质组合物 |
CN108289951A (zh) | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体和缀合物 |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
EP3377040B1 (en) | 2015-11-18 | 2024-03-06 | Si02 Medical Products, Inc. | Pharmaceutical package for ophthalmic formulations |
US10925927B2 (en) * | 2015-11-18 | 2021-02-23 | Formycon Ag | Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist |
KR102343004B1 (ko) | 2015-12-03 | 2021-12-24 | 리제너론 파마슈티칼스 인코포레이티드 | 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 |
IL302211A (en) * | 2015-12-16 | 2023-06-01 | Regeneron Pharma | Preparations and methods for making protein microparticles |
WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
EP3407868A1 (en) * | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
GB201612317D0 (en) * | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
CN117593362A (zh) | 2016-07-29 | 2024-02-23 | 里珍纳龙药品有限公司 | 具有集成电子视觉检查的组装线 |
EA201990317A1 (ru) | 2016-08-16 | 2019-07-31 | Ридженерон Фармасьютикалз, Инк. | Способы определения количества индивидуальных антител из смеси |
WO2018063963A1 (en) * | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
ES2924060T3 (es) | 2016-10-25 | 2022-10-04 | Regeneron Pharma | Procedimientos y sistema para análisis de datos de cromatografía |
US11135266B2 (en) | 2016-11-21 | 2021-10-05 | Just-Evotec Biologics, Inc. | Aflibercept formulations and uses thereof |
US20180207293A1 (en) * | 2017-01-25 | 2018-07-26 | 2C Tech Corp. | Nanoparticles for sustained ophthalmic drug delivery and methods of use |
KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
AU2018266324B2 (en) | 2017-05-06 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
WO2019055902A1 (en) | 2017-09-18 | 2019-03-21 | Amgen Inc. | FUSION PROTEIN FORMULATIONS VEGFR-FC |
US20200338164A1 (en) | 2017-11-17 | 2020-10-29 | Amgen Inc. | Vegfr-fc fusion protein formulations |
WO2019099965A1 (en) | 2017-11-20 | 2019-05-23 | Just Biotherapeutics, Inc. | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
BR112020011072A2 (pt) | 2017-12-13 | 2020-11-17 | Regeneron Pharmaceuticals, Inc. | dispositivos e sistemas para gerenciamento de suporte de leito de coluna cromatográfica e métodos relacionados |
KR20230021164A (ko) * | 2017-12-22 | 2023-02-13 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
JP2021511061A (ja) | 2018-01-26 | 2021-05-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗vegf剤を使用した血管新生障害の治療のための方法および組成物 |
WO2019173767A1 (en) * | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
US20210169871A1 (en) * | 2018-04-05 | 2021-06-10 | Tarveda Therapeutics, Inc. | Pharmaceutical compositions with reduced tert-butanol levels |
TW202348297A (zh) | 2018-05-02 | 2023-12-16 | 美商里珍納龍藥品有限公司 | 用於評估生化過濾器的適合性的方法 |
WO2019217927A1 (en) * | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
WO2020087003A1 (en) | 2018-10-26 | 2020-04-30 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
US20220143137A1 (en) | 2019-02-13 | 2022-05-12 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
MX2022006241A (es) | 2019-11-25 | 2022-08-22 | Univ California | Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular. |
AU2020397803C1 (en) | 2019-12-06 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
KR20230009475A (ko) | 2020-05-11 | 2023-01-17 | 리제너론 파아마슈티컬스, 인크. | 낮은 pH 유지에 의한 바이러스 클리어런스(clearance) |
WO2022019721A1 (ko) | 2020-07-24 | 2022-01-27 | (주) 팬젠 | 안과용 액상 조성물 |
US20230312683A1 (en) * | 2020-07-31 | 2023-10-05 | Celltrion Inc. | Stable pharmaceutical preparation |
KR20220085906A (ko) * | 2020-12-15 | 2022-06-23 | 삼천당제약주식회사 | 안과용 제형을 포함하는 시린지 |
AU2021401301A1 (en) | 2020-12-17 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
WO2023153535A1 (ko) * | 2022-02-09 | 2023-08-17 | 삼천당제약주식회사 | 안과용 제형을 포함하는 시린지 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1046492A (en) | 1907-11-14 | 1912-12-10 | Walter Chisholm Ranson | Flushing apparatus. |
AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
DE69333928T2 (de) | 1992-04-30 | 2006-08-17 | Probitas Pharma Inc., Los Angeles | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
DK2275119T3 (da) | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf結合性ポリペプチド |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
JPH10273450A (ja) * | 1997-03-27 | 1998-10-13 | Toagosei Co Ltd | 眼内血管新生性疾患治療薬 |
DE122005000026I1 (de) | 1997-04-07 | 2005-08-04 | Genentech Inc | Anti-VEGF Antik¦rper. |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
JP2002541849A (ja) | 1999-04-16 | 2002-12-10 | ジェネンテック・インコーポレーテッド | 血管内皮細胞増殖因子変異体とその用途 |
US6887468B1 (en) | 1999-04-28 | 2005-05-03 | Board Of Regents, The University Of Texas System | Antibody kits for selectively inhibiting VEGF |
RS50073B (sr) | 1999-06-08 | 2009-01-22 | Regeneron Pharmaceuticals I.N.C., | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
US6777429B1 (en) | 1999-07-23 | 2004-08-17 | Novartis Ag | Ophthalmic composition |
EP2116265B1 (en) | 2000-10-12 | 2020-12-23 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
WO2003004098A1 (en) | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
CA2466034C (en) | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
GEP20063755B (en) * | 2001-11-09 | 2006-02-27 | Eyetech Pharmaceuticals | Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases |
ES2311094T3 (es) | 2002-02-27 | 2009-02-01 | Immunex Corporation | Composicion estabilizada de tnfr-fc que comprende arginina. |
PL1608685T3 (pl) | 2003-03-28 | 2007-07-31 | Regeneron Pharma | Antagoniści VEGF do leczenia cukrzycy |
CN102258464A (zh) * | 2003-04-04 | 2011-11-30 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
US20040266688A1 (en) | 2003-05-14 | 2004-12-30 | Nayak Nihar R | Methods for modulating endometrium |
EP1626989A2 (en) | 2003-05-28 | 2006-02-22 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
EP1653992A1 (en) | 2003-08-06 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
CN1934255B (zh) | 2003-08-27 | 2012-07-11 | 奥普索特克公司 | 用于治疗眼新血管疾病的组合治疗 |
WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
AU2005222384A1 (en) | 2004-03-05 | 2005-09-22 | Vegenics Limited | Growth factor binding constructs materials and methods |
WO2005102303A2 (en) | 2004-04-21 | 2005-11-03 | Advanced Ocular Systems Limited | Antiprostaglandins for the treatment of ocular pathologies |
CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
ATE548384T1 (de) | 2004-06-08 | 2012-03-15 | Chengdu Kanghong Biotechnologies Co Ltd | Ein die angiogenese inhibierendes chimäres protein und dessen verwendung |
CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
JP2008502738A (ja) | 2004-06-10 | 2008-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトの癌を処置するための、vegfインヒビターの使用 |
US20050281822A1 (en) | 2004-06-18 | 2005-12-22 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion |
CA2567795C (en) | 2004-07-30 | 2013-06-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating type i diabetes by blocking vegf-mediated activity |
SI1802334T1 (sl) * | 2004-10-21 | 2012-12-31 | Genentech, Inc. | Postopek za zdravljenje intraokularnih neovaskularnih bolezni |
EP1877438A2 (en) * | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
ES2548238T3 (es) * | 2005-03-25 | 2015-10-15 | Regeneron Pharmaceuticals, Inc. | Formulaciones antagonistas de VEGF |
KR20080031684A (ko) | 2005-06-14 | 2008-04-10 | 암젠 인코포레이티드 | 자가 - 완충성 단백질 제형 |
CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
DK2944306T3 (da) | 2006-06-16 | 2021-03-08 | Regeneron Pharma | Egnede VEGF-antagonistformuleringer til intravitreal administration |
CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
CN107115294B (zh) | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
RU2634406C1 (ru) | 2014-01-25 | 2017-10-26 | Чэнду Канхун Байотекнолоджиз Ко., Лтд. | Слитый белок, ингибирующий ангиогенез или рост сосудов, и его применение |
US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
-
2007
- 2007-06-14 DK DK15169936.0T patent/DK2944306T3/da active
- 2007-06-14 SI SI200732171T patent/SI2944306T1/sl unknown
- 2007-06-14 KR KR1020087029933A patent/KR101406811B1/ko active IP Right Review Request
- 2007-06-14 WO PCT/US2007/014085 patent/WO2007149334A2/en active Application Filing
- 2007-06-14 CN CN201410707259.XA patent/CN104434770A/zh active Pending
- 2007-06-14 RU RU2009101226A patent/RU2432155C3/ru active
- 2007-06-14 AU AU2007261536A patent/AU2007261536B2/en active Active
- 2007-06-14 CN CNA2007800225554A patent/CN101478949A/zh active Pending
- 2007-06-14 US US11/818,463 patent/US7608261B2/en active Active
- 2007-06-14 MX MX2008016124A patent/MX2008016124A/es active IP Right Grant
- 2007-06-14 PT PT111579652T patent/PT2364691E/pt unknown
- 2007-06-14 CA CA2654510A patent/CA2654510C/en active Active
- 2007-06-14 PT PT151699360T patent/PT2944306T/pt unknown
- 2007-06-14 SI SI200731264T patent/SI2364691T1/sl unknown
- 2007-06-14 LT LTEP15169936.0T patent/LT2944306T/lt unknown
- 2007-06-14 ES ES11157965T patent/ES2406764T3/es active Active
- 2007-06-14 EP EP15169936.0A patent/EP2944306B1/en active Active
- 2007-06-14 EP EP20178021.0A patent/EP3753548A1/en active Pending
- 2007-06-14 HU HUE15169936A patent/HUE053612T2/hu unknown
- 2007-06-14 JP JP2009515517A patent/JP5216002B2/ja active Active
- 2007-06-14 DK DK11157965.2T patent/DK2364691T3/da active
- 2007-06-14 EP EP11157965.2A patent/EP2364691B1/en active Active
- 2007-06-14 BR BRPI0713749A patent/BRPI0713749B8/pt active Search and Examination
- 2007-06-14 ES ES15169936T patent/ES2861898T3/es active Active
- 2007-06-14 PL PL11157965T patent/PL2364691T3/pl unknown
- 2007-06-14 EP EP07809593A patent/EP2029103A2/en not_active Withdrawn
- 2007-06-14 PL PL15169936T patent/PL2944306T3/pl unknown
-
2008
- 2008-11-18 ZA ZA2008/09827A patent/ZA200809827B/en unknown
- 2008-12-08 IL IL195788A patent/IL195788A/en active IP Right Grant
-
2009
- 2009-09-16 US US12/560,885 patent/US7807164B2/en active Active
-
2010
- 2010-07-09 US US12/833,417 patent/US8092803B2/en active Active
-
2011
- 2011-12-19 US US13/329,770 patent/US8481046B2/en active Active
-
2013
- 2013-03-01 JP JP2013040234A patent/JP5597271B2/ja active Active
- 2013-06-11 US US13/914,996 patent/US8802107B2/en active Active
- 2013-07-15 CY CY20131100595T patent/CY1114244T1/el unknown
-
2014
- 2014-07-14 US US14/330,096 patent/US9340594B2/en active Active
-
2015
- 2015-06-02 HK HK15105252.5A patent/HK1204580A1/xx unknown
-
2016
- 2016-04-11 US US15/095,606 patent/US9914763B2/en active Active
- 2016-05-11 US US15/151,776 patent/US9580489B2/en active Active
-
2018
- 2018-01-24 US US15/879,294 patent/US10400025B2/en active Active
- 2018-10-12 US US16/159,269 patent/US10464992B2/en active Active
-
2019
- 2019-09-25 US US16/582,486 patent/US11066458B2/en active Active
-
2020
- 2020-01-10 US US16/739,559 patent/US11084865B2/en active Active
-
2021
- 2021-03-22 CY CY20211100247T patent/CY1124265T1/el unknown
- 2021-06-15 US US17/348,438 patent/US11732024B2/en active Active
-
2023
- 2023-06-29 US US18/344,786 patent/US20230374108A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1204580A1 (en) | Vegf antagonist formulations suitable for intravitreal administration vegf | |
IL227215A (en) | Vegf antagonists | |
EP2001498A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
IL194176A0 (en) | Pharmaceutical compositions | |
GB0713625D0 (en) | Pharmaceutical compositions | |
HK1138732A1 (en) | Pharmaceutical compositions | |
IL194366A0 (en) | Solid dosage formulations | |
EP2112925A4 (en) | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS | |
GB0614586D0 (en) | Pharmaceutical Formulation | |
IL198780A0 (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
ZA201007197B (en) | Raloxifene pharmaceutical formulations | |
IL198160A0 (en) | Pharmaceutical formulations | |
EP2109454A4 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON GLP-1 | |
GB0612556D0 (en) | Topical pharmaceutical formulations | |
GB0615461D0 (en) | Pharmaceutical formulations | |
GB0713093D0 (en) | Pharmaceutical formulations | |
GB0622964D0 (en) | Pharmaceutical compositions | |
GB0609941D0 (en) | Pharmaceutical compositions | |
ZA200808030B (en) | Pharmaceutical compositions | |
HU0600939D0 (en) | Pharmaceutical compositions | |
GB0611079D0 (en) | Pharmaceutical compositions | |
GB0621623D0 (en) | Pharmaceutical compositions | |
HU0600938D0 (en) | Pharmaceutical compositions | |
ZA200904725B (en) | GLP-1 Pharmaceutical compositions |